The short answer: Fallopian tube cancer starts in the thin tubes that carry eggs from the ovaries to the womb. Doctors now know that many cancers once called “ovarian” (especially high-grade serous cancer) actually begin at the end of the fallopian tube, so fallopian tube cancer is staged and treated in the same way as ovarian cancer. Women who carry a BRCA1 or BRCA2 gene change (an inherited fault in a gene that normally helps repair DNA) have a higher risk of both cancers, and removing the tubes and ovaries at the right age lowers that risk. In Hindi this is often searched as fallopian tube ka cancer (फैलोपियन ट्यूब का कैंसर) or, more broadly, andashay ka cancer (अंडाशय का कैंसर).
Many cancers historically labelled “ovarian” are actually fallopian tube in origin. Modern molecular evidence has shifted understanding: most high-grade serous “ovarian” cancers begin in the distal fallopian tube, not the ovary. This has changed how we think about prevention, treatment, and BRCA testing.
On this page
- The clinical shift
- BRCA and fallopian tube cancer
- Prevention — opportunistic salpingectomy
- Treatment
- Outcomes
The clinical shift
Until the early 2000s, fallopian tube cancer was considered a separate, very rare disease. Then molecular studies showed that many cases of advanced “ovarian cancer” (especially high-grade serous) had their origin in the fimbrial end of the fallopian tube — with disease seeding the ovaries and peritoneum from there. The 2014 FIGO staging system formally combined ovarian, fallopian tube, and primary peritoneal cancers because they behave in very similar ways and are treated the same way.
BRCA and fallopian tube cancer
Women with BRCA1 or BRCA2 mutations have significantly elevated lifetime risk of fallopian tube and ovarian cancer. Prophylactic risk-reducing salpingo-oophorectomy (removing both ovaries AND tubes) is recommended at age 35-40 for BRCA1 and 40-45 for BRCA2 carriers. The decision is individualised; reproductive plans matter.
Prevention — opportunistic salpingectomy
For women undergoing hysterectomy for benign indications, removing both fallopian tubes at the same surgery (opportunistic salpingectomy) measurably reduces future ovarian/tubal cancer risk. This has become standard practice in many centres. The ovaries are preserved (important in pre-menopausal women) but the tubes — where most cancers actually start — are removed.
Treatment
Treatment follows the same plan as ovarian cancer of the same stage, and depends on the stage, the type of cancer and your general health. For advanced cancer the usual plan is surgery to remove all visible tumour (cytoreductive surgery) plus carboplatin-paclitaxel chemotherapy. HIPEC (heated chemotherapy inside the abdomen, sometimes called garam chemo) is added only in selected cases, and PARP inhibitor tablets may be offered as maintenance if the cancer is BRCA-positive or HRD-positive (a lab result showing the cancer cannot repair DNA well). Not every option is right for every woman.
Outcomes
Stage-for-stage outcomes are similar to ovarian cancer. Many fallopian tube cancers are found at an advanced stage because early disease often causes few or vague symptoms until it has spread. For what diagnosis and treatment involve, see our page on fallopian tube cancer care and the ovarian cancer overview.
FAQs
If most ovarian cancers actually start in the tube, why isn't this a bigger deal?
It is a big deal — risk-reducing salpingectomy in BRCA carriers and opportunistic salpingectomy in benign hysterectomies are now widely recommended because of this insight.
I had my ovaries out years ago. Am I still at risk?
If the tubes were also removed (salpingo-oophorectomy), risk is dramatically reduced. If only ovaries were removed (oophorectomy with tubes preserved), small residual risk remains, particularly for BRCA carriers.
Can I keep my ovaries but remove just the tubes?
Yes — bilateral salpingectomy is an option for selected younger women who want to preserve ovarian function. Reduces future tubal/ovarian cancer risk meaningfully.
What is the BRCA testing timeline?
Once a personal or family indication exists, testing takes 2-3 weeks. Costs Rs 18,000-35,000. Counselling is recommended pre- and post-test.
Are there other genes besides BRCA?
Yes — Lynch syndrome (MLH1, MSH2, MSH6, PMS2), RAD51C, RAD51D, BRIP1, and PALB2 all have meaningful associations with ovarian/tubal cancer. Modern testing uses multi-gene panels. Our guide to BRCA and Lynch syndrome genetic testing explains who should be tested and what each result means.
Is fallopian tube cancer hereditary?
Sometimes. Some fallopian tube cancers are linked to an inherited gene change, most often in BRCA1 or BRCA2, and less often in the other genes listed above. Many women with tubal cancer have no family history at all, so genetic testing is usually offered to women diagnosed with fallopian tube, ovarian or peritoneal cancer. A positive result can also help close relatives decide about their own testing.
What should I bring to my first appointment?
Bring all scan reports (and CDs if you have them), any biopsy, surgery and pathology reports, CA-125 results, any BRCA or genetic test report, and a note of relatives who had breast, ovarian, pancreatic or prostate cancer. Our checklist on preparing for a specialist appointment covers the rest.
Reviewed by Dr. Nishtha Tripathi Patel, MBBS, DGO, DNB, Fellowship Gynaecological Oncology, ESGO-certified. To book: WhatsApp +91 76988 00333.